Cargando…

PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION

BACKGROUND: KN026 is a novel bispecific antibody and simultaneously binds to two distinct HER2 epitopes which are the same domains as trastuzumab (ECD4) and pertuzumab (ECD2). It showed higher maximal binding than monospecific HER2 antibodies and favors that crosslinking of HER2 receptors could enha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ting, Lv, Yuan, Sun, Jie, Peng, Jianjian, Li, Jingqiu, Li, Xionghui, Guo, Baohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370438/ http://dx.doi.org/10.1093/abt/tbad014.006

Ejemplares similares

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
por: Rau, Alexander, et al.
Publicado: (2021)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
por: Malm, Magdalena, et al.
Publicado: (2016)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
por: James, N D, et al.
Publicado: (2001)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
por: Chen, Yi-Li, et al.
Publicado: (2021)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Preliminary association of circulating tumor cells (CTCs) pre- and post-AdHER2 dendritic cell vaccination with overall survival in patients with metastatic HER2+ solid tumors
por: Tomita, Yusuke, et al.
Publicado: (2015)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

KN and KN two-body physics: 2-5 GeV/c
por: Michael, C
Publicado: (1972)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
por: Lin, Wu, et al.
Publicado: (2023)

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
por: Gu, Chang-ling, et al.
Publicado: (2021)

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

An EGFR/HER2-Bispecific and Enediyne-Energized Fusion Protein Shows High Efficacy against Esophageal Cancer
por: Guo, Xiao-Fang, et al.
Publicado: (2014)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer
por: Waliany, Sarah, et al.
Publicado: (2023)

Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
por: Su, Chia-Yu, et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
por: Piha-Paul, Sarina A., et al.
Publicado: (2021)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
por: Arenas, Enrique J., et al.
Publicado: (2021)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ie3gkbhmc75evb5ke6d5r7d632